Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Retained Earnings (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Retained Earnings for 14 consecutive years, with -$329000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 99.9% year-over-year to -$329000.0, compared with a TTM value of -$329000.0 through Dec 2025, up 99.9%, and an annual FY2025 reading of -$339000.0, down 212.25% over the prior year.
  • Retained Earnings was -$329000.0 for Q4 2025 at Enanta Pharmaceuticals, up from -$339000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $97.2 million in Q1 2021 and bottomed at -$345.3 million in Q4 2024.
  • Average Retained Earnings over 5 years is -$50.8 million, with a median of -$1.1 million recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 15886.68% in 2021, then crashed 19462.3% in 2024.
  • Year by year, Retained Earnings stood at -$1.0 million in 2021, then tumbled by 10055.57% to -$102.2 million in 2022, then plummeted by 135.31% to -$240.4 million in 2023, then crashed by 43.65% to -$345.3 million in 2024, then surged by 99.9% to -$329000.0 in 2025.
  • Business Quant data shows Retained Earnings for ENTA at -$329000.0 in Q4 2025, -$339000.0 in Q3 2025, and -$402000.0 in Q2 2025.